Publications
5539 Results
- Journal / Conference
- Journal of the National Cancer Institute Jun 8;115(6):703-711
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID36946291
- PMC
- PMC10248838
- Study Number(s)
- S1204
Risk Prediction of Hepatitis B or C or HIV Among Newly Diagnosed Cancer Patients
- Journal / Conference
- New England Journal of Medicine May 4;388(18):1645-1656
- Year
- 2023
- Research Committee(s)
- Breast and Cancer Survivorship
- PMID
- PMID37133584
- PMC
- PMC10358451
- Study Number(s)
- CTSU/A221405
Interrupting Endocrine Therapy to Attempt Pregnancy After Breast Cancer
- Journal / Conference
- JCO Oncology Practice Feb;19(2):Feb;19(2):
- Year
- 2023
- PMID
- PMID36480776
Do I Know You? Patient Privacy and Consent in the Age of Social Media
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 6; abstr TPS277); ASCO GU Cancers Symposium (Feb 16-18, 2023, San Francisco, CA), poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
Alliance A031902 (CASPAR): A randomized, phase 3 trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) in first-line metastatic castration-resistant prostate cancer (mCRPC)
- Journal / Conference
- Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Evaluating the impact of stratification, sample size, and randomization ratio on the power of randomized Phase 2 clinical trials
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS4198); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S2001
Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2+) Mutations: SWOG S2001 NCT04548752
- Journal / Conference
- Hematology Oncology Vol 41 Issue S2 Supplement; ICML (June 13 to June 17, 2023, Lugano, Switzerland), oral, plenary session
- Year
- 2023
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826
- Journal / Conference
- Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland, oral
- Year
- 2023
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0016
A “Functional Cure” May be Achievable in a Subset of Patients with Follicular Lymphoma treated with chemoimmunotherapy: 15-Year Follow-Up of Phase III SWOG-S0016
- Journal / Conference
- Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
- Year
- 2023
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S2207
S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL
- Journal / Conference
- Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
- Year
- 2023
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S2114